The Journey of Adalimumab

Adalimumab is administered subcutaneously as a 40 mg dose every
two weeks (or weekly for some indications) because it is a large protein (molecular weight
~148 kDa) that would be degraded in the GI tract and cannot be absorbed intact. Following
subcutaneous injection in the abdomen, thigh, or upper arm, the drug is absorbed primarily via
the lymphatic system rather than direct capillary uptake. Lymphatic transport is slow —
lymph flow rates are approximately 100-fold lower than blood flow — explaining the 5-6 day
time to peak serum concentration. Absolute bioavailability from subcutaneous injection is
approximately 64%. Injection site matters modestly: abdominal injection achieves similar
pharmacokinetics to thigh injection. Adalimumab biosimilars (>30 approved globally) have
demonstrated equivalent pharmacokinetics, efficacy, and safety in regulatory studies.

As a large IgG1 monoclonal antibody, adalimumab distributes
primarily in the vascular compartment and interstitial fluid. Its volume of distribution is
small (approximately 4.7-6 L), consistent with limited tissue penetration beyond blood and
extravascular fluid. Adalimumab concentrates in tissues with active inflammation, where increased
vascular permeability (driven in part by the TNF it inhibits) paradoxically facilitates access.
Drug levels in synovial fluid in rheumatoid arthritis reach approximately 40-50% of serum
concentrations. CNS penetration is minimal under normal circumstances. The IgG1 Fc region
mediates binding to the neonatal Fc receptor (FcRn) on endothelial cells and monocytes, which
recycles adalimumab (and endogenous IgG) back into circulation, protecting it from lysosomal
degradation and accounting for its prolonged half-life.

TNF-alpha (tumor necrosis factor-alpha) is a pleiotropic cytokine
produced primarily by activated macrophages, T cells, and NK cells. It exists as both a soluble
homotrimer (sTNF, cleaved from the membrane by ADAM17/TACE) and as a transmembrane homotrimer
(tmTNF). Both forms activate TNF receptors (TNFR1, constitutively expressed; TNFR2, inducible
on immune cells). TNFR1 signaling via TRADD and RIP1 activates NF-κB and MAPK pathways,
inducing expression of inflammatory mediators (IL-1, IL-6, IL-8, adhesion molecules, MMP),
and can also trigger apoptosis via caspase-8. Adalimumab binds both sTNF and tmTNF with
picomolar affinity (Kd ~1 nM), neutralizing receptor binding. Additionally, binding of
adalimumab to tmTNF-expressing cells induces Fc-mediated reverse signaling (anti-inflammatory
intracellular signaling in the TNF-expressing cell) and ADCC/CDC-mediated cell lysis, which
depletes activated macrophages in the gut lamina propria — the proposed mechanism for induction
of remission in Crohn's disease.

As a protein therapeutic, adalimumab is catabolized by the
same proteolytic pathways as endogenous IgG. There are no CYP enzymes involved. The primary
degradation mechanism involves internalization of the adalimumab-TNF complex (or free antibody)
into lysosomes where endopeptidases cleave the molecule into amino acids and peptides that
are recycled. Immunogenicity — the formation of anti-drug antibodies (ADAs) — is the major
pharmacokinetic concern unique to biologic drugs. ADAs against adalimumab occur in 5-30%
of patients, are more common without concomitant methotrexate (which suppresses ADA formation),
and can dramatically accelerate drug clearance, reducing trough concentrations below therapeutic
thresholds (>5 µg/mL associated with clinical response) and causing loss of efficacy.

Adalimumab is eliminated by protein catabolism; no intact drug
appears in urine. The terminal elimination half-life is approximately 14 days, consistent with
FcRn-mediated recycling of IgG1 antibodies. Clearance is approximately 12 mL/h. In the presence
of high TNF burden (active disease), target-mediated drug disposition (TMDD) — binding of
adalimumab to its target and internalization of the complex — accelerates clearance, creating
concentration-response relationships where disease activity inversely correlates with trough
levels. Conversely, as disease responds to treatment and TNF burden decreases, clearance slows
and trough levels rise. This non-linear pharmacokinetics underlies the rationale for therapeutic
drug monitoring (TDM) and dose adjustment based on trough levels.

Adalimumab (Humira) became the world's best-selling drug for
over a decade, approved across rheumatoid arthritis, Crohn's disease, ulcerative colitis,
plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, uveitis, and hidradenitis
suppurativa. TNF inhibition reactivates latent tuberculosis (mandatory TB screening before
initiation), increases risk of serious bacterial infections and fungal infections, and promotes
demyelinating disease progression (contraindicated in MS). Development of biosimilars after
patent expiration has reduced per-patient cost substantially. Combination with methotrexate
reduces immunogenicity and improves clinical outcomes versus adalimumab monotherapy.